Multiple Sclerosis Clinical Trial
Official title:
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis - CALLIPER
This study will be a multicenter, randomized, double-blind, placebo-controlled study with a blinded Main Treatment Period (MT) and an Open Label Period (OLE) to evaluate the efficacy, safety, and tolerability of IMU838 in adult patients with PMS. The study will consist of the following periods: Screening Period: Approximately 28 days Main Treatment Period: Up to 120 weeks (approximately 2 years) Open Label Extension Period: Up to approximately 8 years ;
| NCT number | NCT05054140 |
| Study type | Interventional |
| Source | Immunic AG |
| Contact | Andreas Muehler, MD |
| Phone | +49 89 2080 477 00 |
| [email protected] | |
| Status | Recruiting |
| Phase | Phase 2 |
| Start date | September 30, 2021 |
| Completion date | July 28, 2024 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
| Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
| Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
| Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
| Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
| Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
| Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
| Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
| Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
| Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
| Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
| Recruiting |
NCT05208840 -
A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis
|
Phase 4 | |
| Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 | |
| Completed |
NCT02845635 -
MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
|
||
| Completed |
NCT02232061 -
Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks
|
Phase 4 | |
| Recruiting |
NCT04990219 -
A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis
|
Phase 1 | |
| Recruiting |
NCT03983681 -
Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS
|
N/A | |
| Enrolling by invitation |
NCT04676204 -
Relationship Between Oral DMT Burden and Adherence in MS
|
||
| Recruiting |
NCT03424733 -
Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects
|
Phase 4 |